

Special Issue

Advances of Amyloid- β Dynamics in Health and Diseases

Message from the Guest Editor

Neurodegenerative diseases, including Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), are characterized by impaired amyloid- β clearance, leading to amyloid- β accumulation. The goal of this Special Issue is to look at the molecular mechanisms that explain the dynamics of amyloid- β and how they relate to neurodegeneration (AD, CAA). We are currently seeking the submission of papers (original research, review articles, mini review articles, and opinions) that investigate multiple mechanisms in the brain and periphery that are involved in the metabolism and clearance of amyloid- β . Interest areas include the blood-brain barrier dynamics, interstitial fluid flow, glial and neuronal cell involvement, enzymatic and non-enzymatic clearance mechanisms, and the interconnections of peripheral organs. Furthermore, there is tremendous potential for research on new targets for preventing amyloid- β deposition and innovative therapeutic approaches to improve amyloid- β clearance. The goal of this Special Issue is to address research gaps, improve understanding of AD pathophysiology, and provide effective strategies for treatment

Guest Editor

Dr. Rahat Ullah

1. Department of Pharmaceutical Sciences, OU College of Pharmacy, University of Oklahoma Health Sciences, 1110 N. Stonewall Avenue, Room No. 259, Oklahoma City, OK 73117, USA
2. Postdoctoral Research Fellow, Department of Neurosciences, Institute for Cell Engineering, School of Medicine, Johns Hopkins University, 733 North Broadway, MRB 720, Baltimore, MD 21205, USA

Deadline for manuscript submissions

closed (28 February 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/209675

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).